The tyrosine kinase v-Src causes mitotic slippage by phosphorylating an inhibitory tyrosine residue of Cdk1

J Biol Chem. 2018 Oct 5;293(40):15524-15537. doi: 10.1074/jbc.RA118.002784. Epub 2018 Aug 22.

Abstract

The nonreceptor tyrosine kinase v-Src is an oncogene first identified in Rous sarcoma virus. The oncogenic effects of v-Src have been intensively studied; however, its effects on chromosomal integrity are not fully understood. Here, using HeLa S3/v-Src cells having inducible v-Src expression, we found that v-Src causes mitotic slippage in addition to cytokinesis failure, even when the spindle assembly checkpoint is not satisfied because of the presence of microtubule-targeting agents. v-Src's effect on mitotic slippage was also observed in cells after a knockdown of C-terminal Src kinase (Csk), a protein-tyrosine kinase that inhibits Src-family kinases and was partially inhibited by PP2, an Src-family kinase inhibitor. Proteomic analysis and in vitro kinase assay revealed that v-Src phosphorylates cyclin-dependent kinase 1 (Cdk1) at Tyr-15. This phosphorylation attenuated Cdk1 kinase activity, resulting in a decrease in the phosphorylation of Cdk1 substrates. Furthermore, v-Src-induced mitotic slippage reduced the sensitivity of the cells to microtubule-targeting agents, and cells that survived the microtubule-targeting agents exhibited polyploidy. These results suggest that v-Src causes mitotic slippage by attenuating Cdk1 kinase activity via direct phosphorylation of Cdk1 at Tyr-15. On the basis of these findings, we propose a model for v-Src-induced oncogenesis, in which v-Src-promoted mitotic slippage due to Cdk1 phosphorylation generates genetic diversity via abnormal cell division of polyploid cells and also increases the tolerance of cancer cells to microtubule-targeting agents.

Keywords: Cdk1; Src; cancer; cell cycle; cyclin-dependent kinase (CDK); microtubule-targeting agent; mitosis; mitotic slippage; pTyr-15; phosphorylation; spindle checkpoint; tyrosine kinase; v-Src.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology*
  • CDC2 Protein Kinase / antagonists & inhibitors
  • CDC2 Protein Kinase / genetics*
  • CDC2 Protein Kinase / metabolism
  • Cell Proliferation / drug effects
  • HeLa Cells
  • Humans
  • Microtubules / drug effects*
  • Microtubules / metabolism
  • Microtubules / ultrastructure
  • Mitosis / drug effects*
  • Oncogene Protein pp60(v-src) / antagonists & inhibitors
  • Oncogene Protein pp60(v-src) / genetics*
  • Oncogene Protein pp60(v-src) / metabolism
  • Paclitaxel / pharmacology*
  • Phosphoproteins / genetics
  • Phosphoproteins / metabolism
  • Phosphorylation
  • Polyploidy
  • Protein Kinase Inhibitors / pharmacology
  • Pyrimidines / pharmacology
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Time-Lapse Imaging

Substances

  • AG 1879
  • Antineoplastic Agents, Phytogenic
  • Phosphoproteins
  • Protein Kinase Inhibitors
  • Pyrimidines
  • RNA, Small Interfering
  • Oncogene Protein pp60(v-src)
  • CDC2 Protein Kinase
  • CDK1 protein, human
  • Paclitaxel